Drug intelligence / Profile preview

FC084

Development stage: Unknown
Lead developer: FindCure Biosciences
Modality: Small Molecules
Administration: Oral

Overview

FC084 is a small molecule inhibitor of Src homology region 2 domain-containing phosphatase 2 (SHP2), developed by Zhongshan Innovision New Drug Research and Development. SHP2 is a non-receptor protein tyrosine phosphatase that plays a critical role in the RAS/MAPK signaling pathway, which is frequently dysregulated in various cancers. By inhibiting SHP2, FC084 aims to suppress tumor growth and overcome resistance to other targeted therapies. It is currently being evaluated in clinical trials, both as a monotherapy and in combination with other agents like the PD-1 inhibitor tislelizumab, for the treatment of advanced solid tumors and lung cancer.

Other names: FC084 camphor sulfonateFC-084 camphor sulfonateFC 084 camphor sulfonate

Targets

PTPN11 (Tyrosine-protein phosphatase non-receptor type 11)

Beyond the preview

Go deeper on FC084.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FC084.

Explore the full profile